|
Treatment
|
Change in mammographic density (%)
|
|---|
| |
Unadjusted mean ± SEM
|
P
|
Adjusted mean ± SEM*
|
P
|
|---|
|
EPAT
| | | | |
|
Placebo (n = 57)
|
- 0.7 ± 0.8
|
Ref.
|
- 0.9 ± 0.9
|
Ref.
|
|
ET (n = 70)
|
3.4 ± 0.7
|
0.003
|
4.0 ± 0.8
|
0.0001
|
|
WELL-HART
| | | | |
|
Placebo (n = 37)
|
0.8 ± 1.4
|
Ref.
|
0.06 ± 1.7
|
Ref.
|
|
ET (n = 34)
|
4.8 ± 1.5
|
0.06
|
5.6 ± 1.5
|
0.02
|
|
EPT (n = 34)
|
7.8 ± 1.5
|
0.001
|
7.8 ± 1.6
|
0.0005
|
|
P homogeneity of treatment effect between trials
| | | |
0.76
|
|
All women
| | | | |
|
Placebo (n = 95)
|
- 0.02 ± 0.8
|
Ref.
|
0.02 ± 0.8
|
Ref.
|
|
ET (n = 104)
|
3.9 ± 0.7
|
0.0003
|
4.6 ± 0.8
|
0.0001
|
|
EPT (n = 34)
|
7.8 ± 1.3
|
0.0001
|
7.2 ± 1.5
|
0.0001
|
- *Adjusted for mammographic percentage density at baseline, race, age at baseline, years since menopause, past use of hormone therapy, body mass index (BMI) at baseline, change in BMI on trial and study group. EPAT, Estrogen in the Prevention of Atherosclerosis Trial; EPT, estrogen and progestin therapy; ET, estrogen therapy; WELL-HART, Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial.
